Rezolute, Inc.

8 articles with Rezolute, Inc.

• 

  BioSpace Movers & Shakers, Sept. 11

  9/11/2020

  Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers.

• Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors

  9/10/2020

  Rezolute, Inc.(“Rezolute” or “the Company”) (OTCQB:RZLT), announced today that the Company has appointed veteran global healthcare executive Philippe Fauchet, O.B.E. to its board of directors.

• Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism

  7/27/2020

  Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today provided an update on the status of the Company’s clinical programs in the context of the global COVID-19 pandemic (“Pandemic”), including its Phase 2b study for RZ358 (“RIZE”) in congenital hyperinsulinism (“CHI”) patients as well as a Phase 1 study for RZ402 in healthy volunteers.

• Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science

  6/15/2020

  Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT), announced that the company’s abstract accepted to the virtual Association for Research in Vision and Ophthalmology (ARVO) 2020 meeting, titled “Nonclinical safety and pharmacology of RZ402, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema as a daily oral therapy,” was published in the peer-reviewed journal Investigative Ophthalmology & Visual Scie

• 

  Clinical Catch-Up: May 31-June 5

  6/8/2020

  As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.

• Rezolute Presents RZ358 Clinical Data-Validated Model of the Pharmacokinetics and Glycemic Response in Congenital Hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting

  6/1/2020

  Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT) recently announced that it has validated pharmacokinetic (PK) and pharmacodynamic (PD) models of its lead clinical asset, RZ358. Phase 2a data in adult and pediatric patients with congenital hyperinsulinism (HI) were shown to be predicted by the constructed models, and demonstrated that RZ358 raises glucose into a normal target range in a disease- and exposure-dependent manner,

• 

  Clinical Catch-Up: May 25-29

  6/1/2020

  In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.

• Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting

  5/28/2020

  Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming oral presentation at this year’s Pediatric Endocrine Society meeting, which will be held virtually. Details of the presentation are as follows: Title: Single Dose Studies of RZ358 in Patients with Congenital Hyperinsulinism: Results of Population PK/PD Modeling and Simulation in Adult and Pediatric Patients Presenter: Brian Roberts, M.D., Rezol